Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.

Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, Prager BC, Shi Y, Zhou W, Bhargava S, Zhu Z, Jiang L, Tao W, Qiu Z, Zhao L, Zhang G, Li X, Agnihotri S, Mischel PS, Mack SC, Bao S, Rich JN.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaau4972. doi: 10.1126/scitranslmed.aau4972.

PMID:
31391321
2.

Acyl-CoA-Binding Protein Fuels Gliomagenesis.

Bi J, Mischel PS.

Cell Metab. 2019 Aug 6;30(2):229-230. doi: 10.1016/j.cmet.2019.07.007.

PMID:
31390546
3.

IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.

Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT.

Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1.

PMID:
31371825
4.

Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.

Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, Kornblum HI, Rich JN, Cloughesy TF, Cavenee WK, Furnari FB, Cravatt BF, Mischel PS.

Cell Metab. 2019 Sep 3;30(3):525-538.e8. doi: 10.1016/j.cmet.2019.06.014. Epub 2019 Jul 11.

PMID:
31303424
5.

Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling.

Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, Wolf M, Lv D, Bhargava S, Jiang L, Prager BC, Wang X, Ye Q, Zhu Z, Zhang G, Dong Z, Zhao L, Lee D, Bi J, Sloan AE, Mischel PS, Brown JM, Cang H, Huan T, Mack SC, Xie Q, Rich JN.

Cancer Discov. 2019 Sep;9(9):1248-1267. doi: 10.1158/2159-8290.CD-19-0061. Epub 2019 Jun 14.

PMID:
31201181
6.

NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.

Chowdhry S, Zanca C, Rajkumar U, Koga T, Diao Y, Raviram R, Liu F, Turner K, Yang H, Brunk E, Bi J, Furnari F, Bafna V, Ren B, Mischel PS.

Nature. 2019 May;569(7757):570-575. doi: 10.1038/s41586-019-1150-2. Epub 2019 Apr 24.

PMID:
31019297
7.

Extrachromosomal oncogene amplification in tumour pathogenesis and evolution.

Verhaak RGW, Bafna V, Mischel PS.

Nat Rev Cancer. 2019 May;19(5):283-288. doi: 10.1038/s41568-019-0128-6. Review.

PMID:
30872802
8.

A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer.

Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, Schultz PG, Mischel PS, Lairson LL.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. doi: 10.1073/pnas.1816626116. Epub 2019 Mar 7.

9.

Exploring the landscape of focal amplifications in cancer using AmpliconArchitect.

Deshpande V, Luebeck J, Nguyen ND, Bakhtiari M, Turner KM, Schwab R, Carter H, Mischel PS, Bafna V.

Nat Commun. 2019 Jan 23;10(1):392. doi: 10.1038/s41467-018-08200-y.

10.

Metabolic reprogramming in the pathogenesis of glioma: Update.

Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N.

Neuropathology. 2019 Feb;39(1):3-13. doi: 10.1111/neup.12535. Epub 2019 Jan 4. Review.

PMID:
30609184
11.

mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression.

Harachi M, Masui K, Okamura Y, Tsukui R, Mischel PS, Shibata N.

Int J Mol Sci. 2018 Oct 21;19(10). pii: E3267. doi: 10.3390/ijms19103267. Review.

12.

Breast cancer treatment and its effects on aging.

Chang L, Weiner LS, Hartman SJ, Horvath S, Jeste D, Mischel PS, Kado DM.

J Geriatr Oncol. 2019 Mar;10(2):346-355. doi: 10.1016/j.jgo.2018.07.010. Epub 2018 Aug 2. Review.

PMID:
30078714
13.

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.

Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG.

Cancers (Basel). 2018 Jul 25;10(8). pii: E243. doi: 10.3390/cancers10080243.

14.

Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context.

Bi J, Wu S, Zhang W, Mischel PS.

Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):76-87. doi: 10.1016/j.bbcan.2018.05.002. Epub 2018 May 23. Review.

15.

ViFi: accurate detection of viral integration and mRNA fusion reveals indiscriminate and unregulated transcription in proximal genomic regions in cervical cancer.

Nguyen ND, Deshpande V, Luebeck J, Mischel PS, Bafna V.

Nucleic Acids Res. 2018 Apr 20;46(7):3309-3325. doi: 10.1093/nar/gky180.

16.

Molecular and Genetic Determinants of Glioma Cell Invasion.

Masui K, Kato Y, Sawada T, Mischel PS, Shibata N.

Int J Mol Sci. 2017 Dec 4;18(12). pii: E2609. doi: 10.3390/ijms18122609. Review.

17.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

18.

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.

Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA.

Nat Med. 2017 Nov;23(11):1342-1351. doi: 10.1038/nm.4418. Epub 2017 Oct 9.

19.

Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma.

Liu F, Mischel PS.

Wiley Interdiscip Rev Syst Biol Med. 2018 Jan;10(1). doi: 10.1002/wsbm.1398. Epub 2017 Sep 11. Review.

20.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB.

Genes Dev. 2017 Jun 15;31(12):1212-1227. doi: 10.1101/gad.300079.117. Epub 2017 Jul 19.

21.

mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS.

Mol Cell. 2017 Jul 6;67(1):128-138.e7. doi: 10.1016/j.molcel.2017.05.030. Epub 2017 Jun 22.

22.

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling.

Liu F, Mischel PS, Cavenee WK.

NPJ Precis Oncol. 2017 Mar 20;1(1):1. doi: 10.1038/s41698-017-0005-2. eCollection 2017. Review.

23.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS.

Nature. 2017 Mar 2;543(7643):122-125. doi: 10.1038/nature21356. Epub 2017 Feb 8.

24.

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS.

Cancer Cell. 2016 Nov 14;30(5):683-693. doi: 10.1016/j.ccell.2016.09.008. Epub 2016 Oct 13.

25.

mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.

Masui K, Shibata N, Cavenee WK, Mischel PS.

Bioessays. 2016 Sep;38(9):839-44. doi: 10.1002/bies.201600026. Epub 2016 Jul 18. Review.

26.

Challenges in identifying cancer genes by analysis of exome sequencing data.

Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, Ideker T.

Nat Commun. 2016 Jul 15;7:12096. doi: 10.1038/ncomms12096.

27.

PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.

Agnihotri S, Golbourn B, Huang X, Remke M, Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, Mackenzie D, Rakopoulos P, Ramaswamy V, Taccone MS, Mischel PS, Fuller GN, Hawkins C, Stanford WL, Taylor MD, Zadeh G, Rutka JT.

Cancer Res. 2016 Aug 15;76(16):4708-19. doi: 10.1158/0008-5472.CAN-15-3079. Epub 2016 Jun 20.

28.

Cancer metabolism as a central driving force of glioma pathogenesis.

Masui K, Cavenee WK, Mischel PS.

Brain Tumor Pathol. 2016 Jul;33(3):161-8. doi: 10.1007/s10014-016-0265-5. Epub 2016 Jun 13. Review.

29.

Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma.

Villa GR, Mischel PS.

Nat Neurosci. 2016 May 26;19(6):765-7. doi: 10.1038/nn.4302. Review. No abstract available.

PMID:
27227363
30.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B.

Cancer Cell. 2016 Apr 11;29(4):563-573. doi: 10.1016/j.ccell.2016.03.012.

31.

Molecular classification of gliomas.

Masui K, Mischel PS, Reifenberger G.

Handb Clin Neurol. 2016;134:97-120. doi: 10.1016/B978-0-12-802997-8.00006-2. Review.

PMID:
26948350
32.

Single-cell analysis tools for drug discovery and development.

Heath JR, Ribas A, Mischel PS.

Nat Rev Drug Discov. 2016 Mar;15(3):204-16. doi: 10.1038/nrd.2015.16. Epub 2015 Dec 16. Review.

33.

Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource.

Villa GR, Mischel PS.

EBioMedicine. 2015 Sep 24;2(10):1274-5. doi: 10.1016/j.ebiom.2015.09.033. eCollection 2015 Oct. No abstract available.

34.

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.

Masui K, Cavenee WK, Mischel PS.

Brain Pathol. 2015 Nov;25(6):755-9. doi: 10.1111/bpa.12307. Review.

35.

Metabolic Reprogramming in Brain Cancer: A Coordinated Effort.

Venneti S, Mischel PS.

Brain Pathol. 2015 Nov;25(6):753-4. doi: 10.1111/bpa.12308. No abstract available.

36.

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS.

Mol Cell. 2015 Oct 15;60(2):307-18. doi: 10.1016/j.molcel.2015.09.002. Epub 2015 Oct 8.

37.

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN.

Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15.

38.

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9406-11. doi: 10.1073/pnas.1511759112. Epub 2015 Jul 13.

39.

Significance of filamin A in mTORC2 function in glioblastoma.

Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F.

Mol Cancer. 2015 Jul 2;14:127. doi: 10.1186/s12943-015-0396-z.

40.

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS.

Nat Rev Cancer. 2015 May;15(5):302-10. doi: 10.1038/nrc3918. Epub 2015 Apr 9. Review.

41.

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.

Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E.

J Clin Invest. 2015 Apr;125(4):1591-602. doi: 10.1172/JCI78239. Epub 2015 Mar 23.

42.

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.

Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS.

Cancer Biol Med. 2014 Dec;11(4):255-63. doi: 10.7497/j.issn.2095-3941.2014.04.004. Review.

43.

Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.

Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. doi: 10.1073/pnas.1422640112. Epub 2015 Jan 12.

44.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB.

Cancer Res. 2015 Jan 15;75(2):394-404. doi: 10.1158/0008-5472.CAN-14-2004. Epub 2014 Nov 28.

45.

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A.

Clin Cancer Res. 2014 Nov 15;20(22):5808-22. doi: 10.1158/1078-0432.CCR-14-0234. Epub 2014 Sep 15.

46.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY.

Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26. Review.

47.
48.

mTORC2 in the center of cancer metabolic reprogramming.

Masui K, Cavenee WK, Mischel PS.

Trends Endocrinol Metab. 2014 Jul;25(7):364-73. doi: 10.1016/j.tem.2014.04.002. Epub 2014 May 21.

49.

Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.

Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M.

J Biol Chem. 2014 May 16;289(20):13974-85. doi: 10.1074/jbc.M113.543728. Epub 2014 Mar 18.

50.

mTORC2 dictates Warburg effect and drug resistance.

Masui K, Cavenee WK, Mischel PS.

Cell Cycle. 2014;13(7):1053-4. doi: 10.4161/cc.28377. Epub 2014 Feb 28. No abstract available.

Supplemental Content

Loading ...
Support Center